Breaking News Instant updates and real-time market news.

IRWD

Ironwood

$16.01

-0.06 (-0.37%)

07:51
12/22/16
12/22
07:51
12/22/16
07:51

Ironwood to host conference call

Conference call to discuss the results of the linaclotide colonic release Phase IIb clinical trial will be held on December 22 at 8:30 am. Webcast Link

  • 22

    Dec

IRWD Ironwood
$16.01

-0.06 (-0.37%)

04/26/16
JPMS
04/26/16
NO CHANGE
JPMS
Ironwood Linzess safety concerns overblown, says JPMorgan
04/26/16
COWN
04/26/16
NO CHANGE
COWN
Outperform
Ironwood short report does not discuss any new information, says Cowen
Cowen analyst Boris Peaker,commented on the short report on Ironwood (IRWD) issued by Phase Five Research and said it doesn't appear to discuss any new data. Peaker said the analysis ignores the co-morbidities of patients that are on Linzess, which has been in 2M patients, many with significant other illnesses and on multiple other background therapies. Additionally, the report overlooked the acquisition of Zurampic today from AstraZeneca (AZN) that was favorably structured with a $100M upfront payment to Ironwood, the analyst said. Peaker said feedback on Linzess from consultants at Cowen's Healthcare Conference was positive and reiterates his Outperform rating.
04/27/16
UBSW
04/27/16
NO CHANGE
Target $8
UBSW
Sell
Ironwood had no new safety concerns with Linzess, says UBS
UBS said the FDA had no new safety concerns and there were no regulatory actions required for Ironwood's Linzess drug. The firm expects the noise from yesterday's short report, which suggested the FDA had issues with Linzess, to subside as the safety concerns pointed to were not justified. UBS acknowledges they have not given much credit for the company's pipeline, but they prefer to stay on the sidelines and take a "wait and see" attitude. UBS maintained its Sell rating and $8 price target on Ironwood shares.
12/13/16
EVER
12/13/16
NO CHANGE
Target $296
EVER
Buy
Evercore says Linzess trial an 'under the radar' potential catalyst for Allergan
Evercore ISI analyst Umer Raffat said the readout of the Phase 2b trial of colonic-release Linzess, which is due before year end according to Ironwood (IRWD), is a "wayyy under the radar" potential catalyst for Allergan (AGN), which he notes is partnered on the drug. Expectations are "basically" for the trial to fail completely, but if formulation 1 of colonic release delivers Linzess-like efficacy or has better pain relief than Linzess, it would extend the tail or possibly grow the franchise, he said. In a "blue sky scenario," formulation 2 of colonic release would show good abdominal pain relief, which would open up several new indications for the drug, added Raffat, who has a Buy rating and $296 price target on Allergan shares.

TODAY'S FREE FLY STORIES

BXP

Boston Properties

$122.03

-0.4 (-0.33%)

07:46
08/17/17
08/17
07:46
08/17/17
07:46
Downgrade
Boston Properties rating change  »

Boston Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LFC

China Life Insurance

$15.24

0.04 (0.26%)

07:46
08/17/17
08/17
07:46
08/17/17
07:46
Downgrade
China Life Insurance rating change  »

China Life Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$106.04

0.14 (0.13%)

07:46
08/17/17
08/17
07:46
08/17/17
07:46
Upgrade
Hershey rating change  »

Hershey upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVLT

Revolution Lighting

$6.82

-0.03 (-0.44%)

07:42
08/17/17
08/17
07:42
08/17/17
07:42
Hot Stocks
Revolution Lighting awarded DoD contract »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOLD

Amicus

$12.60

0.31 (2.52%)

, IRWD

Ironwood

$14.92

0.06 (0.40%)

07:42
08/17/17
08/17
07:42
08/17/17
07:42
Recommendations
Amicus, Ironwood, Otonomy, Sarepta, Ignyta analyst commentary  »

JPMorgan lists top SMID…

FOLD

Amicus

$12.60

0.31 (2.52%)

IRWD

Ironwood

$14.92

0.06 (0.40%)

OTIC

Otonomy

$19.35

-0.1 (-0.51%)

SRPT

Sarepta

$37.43

0.72 (1.96%)

RXDX

Ignyta

$9.80

0.1 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 26

    Sep

CSVI

Computer Services

$46.50

0.45 (0.98%)

07:41
08/17/17
08/17
07:41
08/17/17
07:41
Hot Stocks
Computer Services announces retirement of president R. Stanley Eckenberg »

Computer Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROIC

Retail Opportunity

$20.14

0.09 (0.45%)

07:40
08/17/17
08/17
07:40
08/17/17
07:40
Upgrade
Retail Opportunity rating change  »

Retail Opportunity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$159.50

1.75 (1.11%)

07:39
08/17/17
08/17
07:39
08/17/17
07:39
Hot Stocks
Alibaba: 'The numbers speak for themselves' »

Alibaba said on its Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

AAPL

Apple

$160.94

-0.68 (-0.42%)

07:38
08/17/17
08/17
07:38
08/17/17
07:38
Periodicals
Apple Watch may not support voice calls at launch, AI reports »

The new LTE-connected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

WMT

Wal-Mart

$80.98

0.21 (0.26%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Hot Stocks
Breaking Hot Stocks news story on Wal-Mart »

Wal-Mart drops 2.3% in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 16

    Nov

  • 20

    Feb

TDOC

Teladoc

$30.05

-1.15 (-3.69%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Recommendations
Teladoc analyst commentary  »

Teladoc to benefit from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 11

    Sep

AERI

Aerie Pharmaceuticals

$52.20

-0.2 (-0.38%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Recommendations
Aerie Pharmaceuticals analyst commentary  »

Aerie Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 28

    Feb

BABA

Alibaba

$159.50

1.75 (1.11%)

, MU

Micron

$30.69

1.01 (3.40%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

BABA

Alibaba

$159.50

1.75 (1.11%)

MU

Micron

$30.69

1.01 (3.40%)

FCX

Freeport McMoRan

$14.77

0.8 (5.73%)

VALE

Vale

$10.10

0.32 (3.27%)

RIG

Transocean

$7.58

-0.33 (-4.17%)

MPC

Marathon Petroleum

$51.06

-0.83 (-1.60%)

COTY

Coty

$19.67

0.11 (0.56%)

PAGP

Plains GP Holdings

$20.35

-0.46 (-2.21%)

ETSY

Etsy

$15.60

-0.04 (-0.26%)

FOLD

Amicus

$12.60

0.31 (2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

  • 22

    Aug

  • 29

    Aug

  • 29

    Aug

  • 06

    Sep

  • 08

    Nov

REG

Regency Centers

$65.52

0.46 (0.71%)

07:34
08/17/17
08/17
07:34
08/17/17
07:34
Upgrade
Regency Centers rating change  »

Regency Centers upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COMM

CommScope

$32.85

0.01 (0.03%)

07:34
08/17/17
08/17
07:34
08/17/17
07:34
Upgrade
CommScope rating change  »

CommScope upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

MSG

Madison Square Garden

$217.42

1.33 (0.62%)

07:33
08/17/17
08/17
07:33
08/17/17
07:33
Earnings
MSG reports Q4 EPS ($3.58), may not compare to consensus ($1.39) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

ARAY

Accuray

$4.00

-0.1 (-2.44%)

07:32
08/17/17
08/17
07:32
08/17/17
07:32
Hot Stocks
Accuray's Radixact system used by Summit Cancer Center-Boise for the first time »

Accuray and the Summit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

AMOV

America Movil, also tag AMX

$18.51

-0.07 (-0.38%)

, AMX

America Movil, also tag AMOV

$18.82

0.22 (1.18%)

07:32
08/17/17
08/17
07:32
08/17/17
07:32
Periodicals
Mexican Supreme Court rules for America Movil on interconnection fees, WSJ says »

Mexico's Supreme…

AMOV

America Movil, also tag AMX

$18.51

-0.07 (-0.38%)

AMX

America Movil, also tag AMOV

$18.82

0.22 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$21.41

0.23 (1.09%)

07:31
08/17/17
08/17
07:31
08/17/17
07:31
Hot Stocks
Golden Entertainment completes syndication of financing to fund American deal »

Golden Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$8.65

0.06 (0.70%)

, CBI

CB&I

$9.97

-1.22 (-10.90%)

07:30
08/17/17
08/17
07:30
08/17/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

PBR

Petrobras

$8.65

0.06 (0.70%)

CBI

CB&I

$9.97

-1.22 (-10.90%)

URBN

Urban Outfitters

$19.76

2.94 (17.48%)

CL

Colgate-Palmolive

$71.93

0.13 (0.18%)

AXON

Axovant Sciences

$21.80

-0.83 (-3.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

CSCO

Cisco

$32.34

0.25 (0.78%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
Cisco analyst commentary  »

Cisco stock likely range…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

LB

L Brands

$38.95

0.5 (1.30%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
L Brands analyst commentary  »

L Brands share losses may…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

CSCO

Cisco

$32.34

0.25 (0.78%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
Cisco analyst commentary  »

Cisco 'slowly moving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

CCL

Carnival

$68.87

0.16 (0.23%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
Carnival analyst commentary  »

Carnival price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTNA

Quantenna Communications

$17.79

-0.23 (-1.28%)

07:27
08/17/17
08/17
07:27
08/17/17
07:27
Conference/Events
Quantenna Communications management to meet with Deutsche Bank »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 23

    Aug

  • 12

    Sep

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.